Sterility Clinical Trial
Official title:
HyFoSy Versus HSG as a Diagnostic Technique for Tubal Patency: a Prospective Case-control Study.
Verified date | October 2021 |
Source | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Observational, single-center, prospective case-control study, in which each patient is his own control. It focuses on the study of tubal patency and establishing the agreement of results between HyFoSy and HSG.
Status | Active, not recruiting |
Enrollment | 112 |
Est. completion date | November 1, 2022 |
Est. primary completion date | September 1, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 39 Years |
Eligibility | Inclusion Criteria: - Women between 18-39 years, under study for primary sterility, with BMI <30, AMH> 0.6 (good ovarian reserve), subsidiaries of Conjugal or Donor IA, according to the 2019 SAS Reproduction Guide. Exclusion Criteria: - Women <19 or> 39 years old, BMI> 30, secondary sterility, previous tubal sterilization, that is, the ART exclusion criteria according to the 2019 SAS Reproduction Guide. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario Virgen macarena | Sevilla |
Lead Sponsor | Collaborator |
---|---|
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Study of tubal patency and establish the concordance of results between HyFoSy and HSG. | Concordance study between HyFoSy and HSG. It is a qualitative study (yes / no). | Up to 48 weeks. | |
Secondary | Rate of occurrence of complications in the patients included in the study. | Expand the knowledge of the complications in the clinical practice of HyFoSy, confirming the lower perception of pain and the therapeutic effect of HyFoSy. | Up to 48 weeks. | |
Secondary | Time costs of performing HyFoSy versus HSG. | Compare the time it takes to see the effect of the study drug compared to HSG. | Up to 48 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01955356 -
Embryo Implantation After Induced Endometrial Injury
|
N/A | |
Completed |
NCT01330784 -
Assessment of the Therapeutic Utility of hMG-HP
|
N/A | |
Completed |
NCT01330771 -
Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
|
N/A | |
Completed |
NCT04605003 -
Effectiveness of Nasal Endoscope Sterilization Using a Novel Rig-S™ Device
|
N/A | |
Completed |
NCT02607319 -
Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
|
Phase 4 | |
Completed |
NCT01331720 -
Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
|
N/A | |
Completed |
NCT01331733 -
Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
|
N/A | |
Not yet recruiting |
NCT02648555 -
A Lifestyle Intervention to Improve in Vitro Fertilization Results
|
N/A | |
Suspended |
NCT00749853 -
Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
|
Phase 3 | |
Recruiting |
NCT03177122 -
Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
|
Phase 4 | |
Completed |
NCT03169166 -
The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
|
Phase 4 | |
Completed |
NCT01406964 -
Chlamidia Antibodies Test for Tubal Factor Screening
|
N/A | |
Completed |
NCT01430650 -
Endometrial Priming for Embryo Transfer
|
Phase 4 | |
Completed |
NCT03173404 -
Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection
|
N/A | |
Completed |
NCT03561129 -
Embryotransfer Operator and Pregnancy Rate
|
||
Recruiting |
NCT05173597 -
Real-world Evidence on Follitropin Delta Individual Dosing
|
||
Recruiting |
NCT04026282 -
To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment
|
N/A | |
Completed |
NCT03619707 -
Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
|
Phase 4 |